10:57 AM ET
Earnings Call
▶ Call
EyePoint Earnings Call: Key Takeaways
EyePoint is pivoting to Diabetic Macular Edema (DME) after Phase 3 Wet AMD trials failed, implementing a 53% workforce reduction to preserve cash.
- Call
- Nov 12, 2026, 8:30 AM ET